Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of... von Wallentin, Lars, Prof, Yusuf, Salim, Prof, Ezekowitz, Michael D, Prof, Alings, Marco, MD, Flather, Marcus, MD, Franzosi, Maria Grazia, PhD, Pais, Prem, Prof, Dans, Antonio, Prof, Eikelboom, John, MD, Oldgren, Jonas, MD, Pogue, Janice, PhD, Reilly, Paul A, PhD, Yang, Sean, MSc, Connolly, Stuart J, Prof

Volltext

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial von Diener, Hans-Christoph, Prof, Connolly, Stuart J, Prof, Ezekowitz, Michael D, Prof, Wallentin, Lars, Prof, Reilly, Paul A, PhD, Yang, Sean, MSc, Xavier, Denis, MD, Di Pasquale, Giuseppe, Prof, Yusuf, Salim, Prof

Volltext

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran von Pollack, Charles V., Reilly, Paul A., Bernstein, Richard, Dubiel, Robert, Eikelboom, John, Glund, Stephan, Huisman, Menno V., Hylek, Elaine, Kam, Chak-Wah, Kamphuisen, Pieter W., Kreuzer, Joerg, Levy, Jerrold H., Sellke, Frank, Stangier, Joachim, Steiner, Thorsten, Wang, Bushi, Weitz, Jeffrey I.

Volltext

Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation von Aulin, Julia, MD, Siegbahn, Agneta, MD, PhD, Hijazi, Ziad, MD, PhD, Ezekowitz, Michael D., MB, ChB, Andersson, Ulrika, MSc, Connolly, Stuart J., MD, Huber, Kurt, MD, PhD, Reilly, Paul A., PhD, Wallentin, Lars, MD, PhD, Oldgren, Jonas, MD, PhD

Volltext

Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran von Ezekowitz, Michael D., MBChB, DPhil, Connolly, Stuart, MD, Parekh, Amit, MD, Reilly, Paul A., PhD, Varrone, Jeanne, MD, Wang, Susan, PhD, Oldgren, Jonas, MD, PhD, Themeles, Ellison, Wallentin, Lars, MD, PhD, Yusuf, Salim, FRCP(c), FRSC, DPhil

Volltext

Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial von Bytzer, Peter, Connolly, Stuart J, Yang, Sean, Ezekowitz, Michael, Formella, Stephan, Reilly, Paul A, Aisenberg, James

Volltext

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study) von Ezekowitz, Michael D., MD, PhD, Reilly, Paul A., PhD, Nehmiz, Gerhard, PhD, Simmers, Timothy A., MD, Nagarakanti, Rangadham, MD, Parcham-Azad, Kambiz, MD, Pedersen, K. Erik, MD, Lionetti, Dominick A., MA, Stangier, Joachim, PhD, Wallentin, Lars, MD, PhD

Volltext

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects von Reilly, Paul A., PhD, van Ryn, Joanne, PhD, Grottke, Oliver, MD, PhD, Glund, Stephan, PhD, Stangier, Joachim, PhD

Volltext

Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation: Sub-Analysis in Japanese Population in RE-LY Trial von Hori, Masatsugu, Connolly, Stuart J., Ezekowitz, Michael D., Reilly, Paul A., Yusuf, Salim, Wallentin, Lars, Investigators, the RE-LY

Volltext

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy von Hijazi, Ziad, Oldgren, Jonas, Andersson, Ulrika, Connolly, Stuart J, Ezekowitz, Michael D, Hohnloser, Stefan H, Reilly, Paul A, Siegbahn, Agneta, Yusuf, Salim, Wallentin, Lars

Volltext

Novel oral anticoagulants and reversal agents: Considerations for clinical development von Sarich, Troy C., PhD, Seltzer, Jonathan H., MD, Berkowitz, Scott D., MD, Costin', James, MD, Curnutte, John T., MD, Gibson, C. Michael, MD, Hoffman, Maureane, MD, PhD, Kaminskas, Edvardas, MD, Krucoff, Mitchell W., MD, Levy, Jerrold H., MD, Mintz, Paul D., MD, Reilly, Paul A., PhD, Sager, Philip T., MD, Singer, Daniel E., MD, Stockbridge, Norman, MD, PhD, Weitz, Jeffrey I., DM, Kowey, Peter R., MD

Volltext

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects von Reilly, Paul A., PhD, van Ryn, Joanne, PhD, Grottke, Oliver, MD, PhD, Glund, Stephan, PhD, Stangier, Joachim, PhD

Volltext

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies von Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan

Volltext

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: The RE-LY Trial (... von REILLY, Paul A, LEHR, Thorsten, HAERTTER, Sebastian, CONNOLLY, Stuart J, YUSUF, Salim, EIKELBOOM, John W, EZEKOWITZ, Michael D, NEHMIZ, Gerhard, SUSAN WANG, WALLENTIN, Lars

Volltext

Newly Identified Events in the RE-LY Trial von Reilly, Paul A, Connolly, Stuart J, Yusuf, Salim, Ezekowitz, Michael D, Wallentin, Lars

Volltext

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score von Hori, Masatsugu, Fukaya, Taku, Kleine, Eva, Reilly, Paul A, Ezekowitz, Michael D., Connolly, Stuart J, Investigators, the RE-LY

Volltext

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis von Pollack, Charles V, Reilly, Paul A, van Ryn, Joanne, Eikelboom, John W, Glund, Stephan, Bernstein, Richard A, Dubiel, Robert, Huisman, Menno V, Hylek, Elaine M, Kam, Chak-Wah, Kamphuisen, Pieter W, Kreuzer, Jörg, Levy, Jerrold H, Royle, Gordon, Sellke, Frank W, Stangier, Joachim, Steiner, Thorsten, Verhamme, Peter, Wang, Bushi, Young, Laura, Weitz, Jeffrey I

Volltext

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial von DANS, Antonio L, CONNOLLY, Stuart J, YUSUF, Salim, WALLENTIN, Lars, YANG, Sean, NAKAMYA, Juliet, BRUECKMANN, Martina, EZEKOWITZ, Michael, OLDGREN, Jonas, EIKELBOOM, John W, REILLY, Paul A

Volltext

Idarucizumab for Dabigatran Reversal von Pollack, Charles V, Reilly, Paul A, Eikelboom, John, Glund, Stephan, Verhamme, Peter, Bernstein, Richard A, Dubiel, Robert, Huisman, Menno V, Hylek, Elaine M, Kamphuisen, Pieter W, Kreuzer, Jörg, Levy, Jerrold H, Sellke, Frank W, Stangier, Joachim, Steiner, Thorsten, Wang, Bushi, Kam, Chak-Wah, Weitz, Jeffrey I

Volltext

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial von HART, Robert G, DIENER, Hans-Christoph, SEAN YANG, CONNOLLY, Stuart J, WALLENTIN, Lars, REILLY, Paul A, EZEKOWITZ, Michael D, YUSUF, Salim

Volltext